Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma

Cancer Investigation

Volumn 32, Issue 6, 2014, Pages 218-225

  Jiang, Bing ^a   Gu, Yonghong ^a   Chen, Yuxiang ^b  

^a THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

IGF 1 receptor; Klotho; Methylation; miR 504; Pancreatic ductal adenocarcinoma; Prognosis

Indexed keywords

KLOTHO PROTEIN; MICRORNA; MICRORNA 504; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KLOTHO GENE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

IGF-1 RECEPTOR; KLOTHO; METHYLATION; MIR-504; PANCREATIC DUCTAL ADENOCARCINOMA; PROGNOSIS;

ADENOCARCINOMA; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIDASE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, IGF TYPE 1; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902177413     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2014.905586     Document Type: Article

References (29)

1. Spratlin JL, Mulder, KE. Looking to the future: biomarkers in the management of pancreatic adenocarcinoma. Int J Mol Sci 2011;12:5895-5907.
2. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, Beger HG. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997;57:1634-1637.
3. Cohenuram M, Saif MW. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future. JOP 2007;8:4-15.
4. John GB, Cheng CY, Kuro-o M. Role of Klotho in aging, phosphate metabolism, and CKD. Am J Kidney Dis 2011;58:127-134.
5. Pan J, Zhong J, Gan LH, Chen SJ, Jin HC, Wang X, Wang LJ. Klotho, an anti-senescence related gene, is frequently inactivated through promoter hypermethylation in colorectal cancer. Tumour Biol 2011;32:729-735.
6. RubinekT, ShulmanM, Israeli S, Bose S, AvrahamA,Zundelevich A, Evron E, Gal-YamEN, Kaufman B,Wolf I. Epigenetic silencing of the tumor suppressor klotho in human breast cancer. Breast Cancer Res Treat 2012;133:649-657.
7. Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression. Cancer Invest 2008;26:185-192.
8. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-1489.
9. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P,McGuinnessOP, Chikuda H, YamaguchiM, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro-o M. Kuro-o, Suppression of aging in mice by the hormone Klotho. Science 2005;309:1829-1833.
10. Arking DE, Becker DM, Yanek LR, Fallin D, Judge DP, Moy TF, Becker LC, Dietz HC. KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 2003;72:1154-1161.
11. Chen CD, Podvin S, Gillespie E, Leeman SE, CAbraham CR. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA 2007;104:19796-19801.
12. Xie B, Zhu J, Yuan L, Ren F, Liu D, Li Q, Shu G. Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Hum Pathol 2013;44:795-801.
13. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-2261.
14. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2011;11:610.
15. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2003;302:1-12.
16. Hu W, Chan CS,Wu R, Zhang C, Sun Y, Song JS, Tang LH, Levine AJ, Feng Z. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell 2010;38:689-699.
17. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008;9:102-114.
18. Lewis BP, Shih IH, Jones-Rhoades MW,BartelDP, Burge CB. Prediction ofmammalian microRNA targets. Cell 2003;115:787-798.
19. Sobin, LH, Gospodarowicz, MK,Wittekind, C. UICC-TNM classification of malignant tumours. New York, NY:Wiley-Liss, 2009, pp. 132-135.
20. Abramovitz L, Rubinek T, Ligumsky H, Bose S, Barshack I, Avivi C, Kaufman B, Wolf I. KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Clin Cancer Res 2011;17:4254-4266.
21. Zhang X, Li Y, Huang Q,Wang H, Yan B, Dewhirst MW, Li CY. Increased resistance of tumor cells to hyperthermia mediated by integrin-linked kinase. Clin Cancer Res 2003;9:1155-1160.
22. Yamada T, Sato K, KomachiM,Malchinkhuu E, Tobo M, Kimura T, Kuwabara A, Yanagita Y, Ikeya T, Tanahashi Y, Ogawa T, Ohwada S, Morishita Y, Ohta H, Im DS, Tamoto K, Tomura H, Okajima F. Lysophosphatidic acid (LPA) in malignant ascites stimulatesmotility of human pancreatic cancer cells through LPA1. J Biol Chem 2004;279:6595-6605.
23. Komachi M, Tomura H, Malchinkhuu E, Tobo M, Mogi C, Yamada T, Kimura T, Kuwabara A, Ohta H, Im DS, Kurose H, Takeyoshi I, Sato K, Okajima F. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites. Carcinogenesis 2009;30:457-465.
24. Wang L, Wang X, Wang X, Jie P, Lu H, Zhang S, Lin X, Lam EK, Cui Y, Yu J, JinH.Klotho is silenced through promoter hypermethylation in gastric cancer. Am J Cancer Res 2011;1:111-119.
25. Usuda J, Ichinose S, Ishizumi T, Ohtani K, Inoue T, Saji H, Kakihana M, Kajiwara N, Uchida O, Nomura M, Ohira T, Ikeda N. Klotho predicts good clinical outcome in patients with limiteddisease small cell lung cancer who received surgery. Lung Cancer 2011;74:332-337.
26. Bar N, Dikstein R. miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS One 2010;5:e10859.
27. Kumar M, Lu Z, Takwi AA, Chen W, Callander NS, Ramos KS, Young KH, Li Y. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011:30:843-853.
28. Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, Kuro-o M, Karlan B, Kaufman B, Koeffler HP, Rubinek T. Klotho: a tumor suppressor and amodulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 2008;27:7094-7105.
29. Kooijman R. Regulation of apoptosis by insulin-like growth factor (IGF)-I. Cytokine Growth Factor Rev 2006;17:305-323.